News: Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

98.02USD
24 May 2013
Price Change (% chg)

$0.06 (+0.06%)
Prev Close
$97.96
Open
$97.58
Day's High
$98.57
Day's Low
$96.89
Volume
587,503
Avg. Vol
454,161
52-wk High
$116.44
52-wk Low
$81.28

Search Stocks
Select another date:

Wed, May 1 2013

Photo

Allergan delays drug that would rival Regeneron's Eylea

- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

Continue Reading

UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea

May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

Allergan delays eye drug, shares fall

- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.

BRIEF-Regeneron Pharma shares resume trading, up 16 percent

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval

BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3

NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3

Strong Botox sales boost Allergan profit

- Allergan Inc , maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.

Strong Botox sales boost Allergan profit

May 1 - Allergan Inc, maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.

FDA staff says Allergan's new dermal filler effective

April 30 - Reviewers for the U.S. Food and Drug Administration said Allergan Inc's dermal filler, Juvéderm Voluma XC, was effective in correcting volume deficit in the middle of the face at six months of treatment.

Fraudulent versions of Allergan's Botox found in U.S.

- Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.

UPDATE 3-Fraudulent versions of Allergan's Botox found in U.S.

April 26 - Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.

Select another date:

Market Views

» More AGN.N Market Views

Press Releases

Search Stocks